Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Fig. 3

Proportion of patients achieving ASAS PR response through week 16. †P < 0.001, §P < 0.01, ‡P < 0.05 versus placebo. Data presented as NRI through week 16. ASAS, Assessment of SpondyloArthritis international Society; CRP, C-reactive protein; MRI, magnetic resonance imaging; N, total number of patients; NRI, non-responder imputation; PR, partial remission

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us